Vaxcyte Inc - PCVX Earnings per one share for the last 12 months

Official company branding of Vaxcyte Inc (PCVX)

The absence of revenue and the risk of failed trials leave Vaxcyte, Inc. (PCVX) vulnerable to industry behemoths. Reviewing the annual EPS (TTM) growth statistics on GURU.Markets, we see that the level of -65.60 is the current figure. Vaxcyte, Inc. (PCVX) aims to capture the innovative vaccine market through large-scale R&D investments, although high research expenses for pneumococcal drugs and anticipation of the FDA verdict create additional pressure.

Vaxcyte (PCVX): Net earnings per share (EPS TTM) from 02/11/2024 to 11/16/2026

vaxcyte.com - analytical breakdowns and key metrics (PCVX)

- share price and consensus valuation forecast:
Initial company analysis:PCVX, Vaxcyte Inc
Manufactured products of Vaxcyte, Inc.

Vaxcyte, Inc. (PCVX) is optimizing vaccine development through neural network modeling and automated production, which directly impacts operational efficiency. The rolling year earnings per share trend measures the rate of change in net yield, allowing investors to use the EPS YoY TTM growth value to distinguish the actual scale of the business from speculative growth in expectations amid clinical trials.